Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles

MT Newswires Live

2025/09/29

Clinuvel Pharmaceuticals (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.

The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.

If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571875573"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571875573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571875573?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571875573","market":"nz","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.</p><p>The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.</p><p>If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-29 08:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.</p><p>The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.</p><p>If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571875573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571875573","pubTimestamp":1759105587,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals  said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Clinuvel Pharmaceuticals推进研究药物释放曲线的临床前计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) said it progressed a preclinical program evaluating various drug release profiles with sustained-release liquid drug formulations, with the program for the first formulations expected to be completed in the second half of 2026, according to a Monday Australian bourse filing.The formulations the firm is reviewing could facilitate flexible dosing by adjusting the injection volume for the delivery of peptides to infants, children, and adults according to body weight.If the technology is confirmed in vivo, the formulations would serve as a platform to deliver various peptides, with an initial focus on melanocortins.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}